Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771821 | 0.78 | ALDH1A1 (0.36) | ALOX15 | |
| SCHEMBL13257491 | 0.78 | PNMT (0.37) | ALOX15CDK4CCND1 | |
| SCHEMBL7169638 | 0.78 | BAZ2B (0.39) | ALOX15CDK4CCND1 | |
| SCHEMBL9934174 | 0.78 | ALOX15 (0.36) | ALOX15CDK4CCND1 | |
| SCHEMBL16553402 | 0.78 | GABRA1 (0.36) | ALOX15 | |
| SCHEMBL4268689 | 0.75 | HTR2A (0.44) | — | |
| SCHEMBL28324455 | 0.75 | BCL2 (0.45) | ALOX15 | |
| SCHEMBL18937793 | 0.74 | RIPK1 (0.37) | ALOX15 | |
| SCHEMBL3670867 | 0.74 | ALDH1A1 (0.37) | ALOX15 | |
| SCHEMBL2941547 | 0.72 | LIPG (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183613-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-1193020-C | Process for preparing amic acid esters | IHARA CHEMICAL IND CO (JP) | 2005-03-16 | — | — | CN | disclosed |
| US-6576765-B2 | Process for preparing amic acid esters | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20030032667-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-02-13 | — | — | US | disclosed |
| CN-1366523-A | Process for preparing amic acid esters | IHARA CHEMICAL IND CO (JP) | 2002-08-28 | — | — | CN | disclosed |
| US-6384028-B1 | TREATMENT OF CARDIOVASCULAR DISORDERS, ANTICOAGULANTS AND VALVE REPLACEMENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-1182199-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| CN-1041919-C | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as PAF antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-03 | — | — | CN | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
| CN-1116847-A | N- (3-piperidinylcarbonyl) -beta-aminopropionic acid derivatives as PAF antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-02-14 | — | — | CN | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | ALOX15 2668/4885CDK4 4573/4885CCND1 4242/4885 |
| US-20030032667-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | MCCC2, EMC1, GANC | ALOX15 941/4885CDK4 4221/4885CCND1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.